Multiple CoolSculpting Treatment Study
Launched by ZELTIQ AESTHETICS · Mar 14, 2013
Trial Information
Current as of September 26, 2025
Completed
Keywords
ClinConnect Summary
The study will evaluate the safety of multiple same-day CoolSculpting treatments and will assess any impact on serum lips or liver-related analytes,
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Male or female subjects \> 18 years of age.
- * Subject who has been assessed to receive multiple CoolSculpting treatments on the abdomen and flanks, defined as follows:
- • 1. Lower Abdomen - One 60 minute cycle with CoolMax,
- • 2. Right and Left Flank - One 60 minute cycle per flank, with CoolCurve+ or CoolCore, simultaneously.
- • Subject has not had weight change exceeding 10 pounds in the preceding month.
- • Subject with body mass index (BMI) up to 30. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches.
- • Subject agrees to not making any major changes in their diet or lifestyle during the course of the study.
- • Subject has read and signed a written informed consent form.
- • Exclusion Criteria
- • Subject has had an invasive (e.g., liposuction, mesotherapy, abdominoplasty) or non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 6 months.
- • Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
- • Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.
- • Subject has a history of hernia in the area(s) to be treated.
- • Subject is pregnant or intending to become pregnant during the study period (in the next 4 months).
- • Subject is lactating or has been lactating during the past 3 months.
- • Subject is unable or unwilling to comply with the study requirements, such as blood draw.
- • Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
- • Subject has a history of lipodosis or other confounding metabolic diseases.
- • Subject is taking or has taken medication within the past 3 months which may affect the metabolic function.
- • Patient has a history of diabetes.
- • Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
About Zeltiq Aesthetics
Zeltiq Aesthetics, a leader in non-invasive body contouring technologies, specializes in innovative solutions designed to enhance aesthetic outcomes and improve patient experiences. With a focus on scientific research and clinical excellence, the company is renowned for its flagship product, CoolSculpting, which utilizes controlled cooling to target and eliminate stubborn fat cells. Zeltiq is committed to advancing aesthetic medicine through rigorous clinical trials and collaborations, ensuring the safety and effectiveness of its treatments while striving to meet the evolving needs of both healthcare providers and patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pleasanton, California, United States
Walnut Creek, California, United States
Miami, Florida, United States
Patients applied
Trial Officials
Eric Bachelor, MD
Principal Investigator
Innovation Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials